I published a preprint in December 2018: ˝Role of the Th17 cells in the pathophysiology of multiple sclerosis˝.
DOI:
What is your opinion on the role of the Th17 cells in the pathophysiology of multiple sclerosis?
Do you have any experience in the use of secukinumab (anti-IL17A) and ustekinumab (blocks IL12/23, but it has to be reengineered to pass the blood-brain barrier for the use in multiple sclerosis, possibly effective only in the early stage)?
Thank you all in advance!